Go Pro
CVE:LBL

Lattice Biologics (LBL) Stock Price, News & Analysis

C$0.04 0.00 (0.00%)
As of 06/3/2021

About Lattice Biologics Stock (CVE:LBL)

Key Stats

Today's Range
C$0.04
C$0.04
50-Day Range
C$0.04
C$0.04
52-Week Range
C$0.03
C$0.13
Volume
114,000 shs
Average Volume
468,022 shs
Market Capitalization
C$5.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops novel amniotic fluid-based products, such as AmnioBoost and AmnioBlast. The company also offers traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.

Receive LBL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lattice Biologics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LBL Stock News Headlines

Best Lattice Alternatives Of 2024
IVBIY Innovent Biologics, Inc.
Gold just passed our debt as the world's #1 asset
China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low. Beijing's central bank has bought gold for 20 straight months, its longest streak in a decade. Goldman Sachs estimates China's real gold buying is 4.8 times the official figure. The European Central Bank confirms gold has overtaken US Treasuries as the world's top reserve asset, at 27% versus 22%. As foreign demand for US debt fades, rates and everyday costs may feel the pressure.tc pixel
Lattice Biologics Ltd (LBLh)
Lattice Semiconductor Corp LSCC Stock Quote
See More Headlines

LBL Stock Analysis - Frequently Asked Questions

Lattice Biologics' stock was trading at C$0.04 on January 1st, 2026. Since then, LBL stock has increased by 0.0% and is now trading at C$0.04.

Shares of LBL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lattice Biologics investors own include 50904 (GRC.V) (GRC), Air Canada (AC), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Antibe Therapeutics (ATE) and BioCryst Pharmaceuticals (BCRX).

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
CVE:LBL
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.02
Quick Ratio
0.02

Sales & Book Value

Annual Sales
C$1.56 million
Price / Sales
3.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
C$0.00 per share
Price / Book
40.00

Miscellaneous

Outstanding Shares
128,218,000
Free Float
N/A
Market Cap
C$5.13 million
Optionable
Not Optionable
Beta
N/A
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (CVE:LBL) was last updated on 9/14/2026 by MarketBeat.com Staff.
From Our Partners